Table 1.
Currently approved anti-obesity pharmacological treatment.
| Drug Name, Posology | Mechanism of Action | FDA-Approved | EMA-Approved |
|---|---|---|---|
| orlistat, 60–120 mg 3 × 1 tablet daily |
Pancreatic lipase inhibitor | YES (1999) | YES (1998) |
| phentermine/topiramate, 3.75/23 mg; 7.5/46 mg; 11.25/69 mg; 15/92 mg once daily |
Sympathomimetic, appetite suppressant | YES (2012) | NO |
| naltrexone/bupropion, 32/360 mg 2 × 4 tablets daily |
Opioid receptor antagonist/dopamine and noradrenaline reuptake inhibitor | YES (2012) | YES (2015) |
| liraglutide, 3.0 mg injection once daily |
GLP-1 receptor agonist | YES (2014) | YES (2015) |
| semaglutide, 2.4 mg injection once weekly |
GLP-1 receptor agonist | YES (2021) | NO |
Abbreviations: mg, milligram; GLP-1: glucagon-like peptide 1; FDA, Food and Drug Administration; EMA, European Medicines Agency.